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Besides their essential role in hemostasis and thrombosis, platelets are involved in the
onset of cancer metastasis by interacting with tumor cells. Platelets release secretory fac-
tors that promote tumor growth, angiogenesis, and metastasis. Furthermore, the formation
of platelet–tumor cell aggregates in the bloodstream provides cancer cells with an immune
escape mechanism by protecting circulating malignant cells from immune-mediated lysis
by natural killer (NK) cells. Platelet–tumor cell interaction is accomplished by specific adhe-
sion molecules, including integrins, selectins, and their ligands. Podocalyxin-like protein
1 (PCLP1) is a selectin-ligand protein in which overexpression has been associated with
several aggressive cancers. PCLP1 expression enhances cell adherence to platelets in
an integrin-dependent process and through the interaction with P-selectin expressed on
activated platelets. However, the involvement of PCLP1-induced tumor–platelet interaction
in tumor immune evasion still remains unexplored. The identification of selectin ligands
involved in the interaction of platelets with tumor cells may provide help for the develop-
ment of effective therapies to restrain cancer cell dissemination. This article summarizes
the current knowledge on molecules that participate in platelet–tumor cell interaction as
well as discusses the potential role of PCLP1 as a molecule implicated in tumor immune
evasion.
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INTRODUCTION
The metastasis to distant organ sites depends on the interaction
between tumor cells and the microenvironment of the blood-
stream and tissues, including platelets, immune system cells,
endothelial cells, stromal cells, and extracellular matrix (1). The
participation of platelets and coagulation in tumor metastasis
has been observed for a long time (2). Moreover, thrombocy-
tosis and thrombosis have been associated with poor prognosis
in various tumor types (3). These observations and the finding
that suppression of platelet–tumor cell aggregates with antiplatelet
agents inhibits experimental metastasis point to an important role
of platelets in the development of tumor metastasis (4). Dur-
ing platelet–tumor cell interaction, the communication between
both cell types is bilateral, as tumor cells express factors that
trigger platelet activation and coagulation, and activated platelets
promote tumor growth, metastasis, and angiogenesis (5).
The contribution of selectins and its ligands to the communi-
cation between tumor cells and platelets has been confirmed by
several preclinical models (6). Here, we describe the molecules
involved in platelet–tumor interaction, specially focusing on the
mechanisms by which PCLP1, a transmembrane sialomucin with
selectin-ligand activity, participates in platelet–tumor aggregate
formation. We also hypothesize that PCLP1 might be involved
in protecting tumor cell from natural killer (NK) cell-mediated
cytotoxicity.
PLATELETS IN TUMOR PROGRESSION
Metastasis is the main complication and principal cause of death
in most types of cancer. The process of metastasis consists of dif-
ferent phases: (1) detachment of cancer cells from the primary
tumor, (2) intravasation into the vascular system and transport
through the bloodstream, (3) extravasation, and (4) proliferation
in a distant tissue (7, 8).
During circulation through the bloodstream and vascular adhe-
sion at distant sites, tumor cells are prone to death induced by
shear stress and attack of immune cells. However, once tumor
cells intravasate into blood, tumor-derived platelet agonists, such
as adenosine diphosphate (ADP) and thrombin, induce platelet
activation, followed by the formation of heterotypic aggregates
that protect tumor cells from immune attack and physical dam-
age (9, 10). Tissue factor expressed by tumor cells also leads
to thrombin generation through the activation of the coagu-
lation cascade that ultimately results in fibrin formation and
platelet activation (11). These processes, among others, promote
the development of venous thromboembolism in solid tumor and
hematological malignancies, including lymphomas and myeloma,
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and disseminated intravascular coagulation with severe bleed-
ing, which is frequently associated with acute leukemia (12).
The relevance of tumor-induced platelet aggregation in cancer
progression is highlighted by the correlation between the ability
of tumor cells to form platelet aggregates and their metastatic
potential.
Platelets promote tumor cell arrest within the vasculature,
endothelium cell retraction, and subsequent extravasation and
tissue invasion through the release of chemokines, proteolytic
enzymes such as gelatinase and heparanase, various metallopro-
teinases, and microparticules (10). Moreover, platelets contain
proangiogenic and antiangiogenic molecules within α-granules,
which are selectively released depending on the stimuli and are
the most important source of vascular endothelial growth fac-
tor (VEGF). The expression of the proangiogenic molecule VEGF
increases substantially in patients with cancer, promoting the for-
mation of new vessels (13, 14). Platelets also release soluble factors
that increase tumor growth at sites of extravasation. Thrombin and
lysophosphatidic acid (LPA) released by platelets enhance tumor
cell growth and metastasis through the activation of thrombin
receptor PAR1 and LPA receptor, respectively, both expressed on
tumor cells (1).
PLATELETS IN TUMOR IMMUNE EVASION
Platelets also contribute to metastasis by protecting disseminat-
ing tumor cells from NK cell cytolytic activity as supported by
the observation that the antimetastatic effect of platelet removal
is abolished by simultaneous depletion of NK cells (15–17). NK
cells are potent cytolytic lymphocytes of the innate immune sys-
tem that play a critical role in the elimination of tumor cells.
These lymphocytes recognize target cells without prior sensitiza-
tion by means of signals received from activating and inhibitory
receptors, being the balance between these two opposing sig-
nals, which determines the activation state of NK cells (18).
Nevertheless, tumor cells have developed different mechanisms
to evade NK immunosurveillance, including the modulation of
NK receptor–ligand expression patterns and the secretion of
immunoregulatory molecules like IDO and PGE2 or immunosup-
pressive cytokines like IL-10 and tumor growth factor-β (TGF-β)
(19–22).
In early phases of the metastatic process, platelets may sur-
round tumor cells and, in conjunction with fibrinogen, form a
dense coat around tumor cells, providing protection from NK
cell recognition and destruction (23, 24). Besides, both TGF-β
and platelet-derived growth factor (PDGF) secreted by activated
platelets inhibit NK cell effector functions. Particularly, it has been
reported that TGF-β down-regulates the expression of the activat-
ing receptor NKG2D on NK cells after interaction with tumor cells
and, to a lesser extent, NKp30, NKp44, NKp46, and NKp80 expres-
sion (25). Furthermore, TGF-β reduces IFN-γ production by NK
cells and promotes epithelial–mesenchymal-like transition in var-
ious cancer cell lines (26). PDGF diminishes the interaction of NK
with target cells and NK cell cytotoxic activity (27–29). Recently,
it has been reported that glucocorticoid-induced TNF-related lig-
and (GITRL) up-regulated upon platelet activation inhibits NK
cell cytotoxicity and IFN-γ production via GITR expressed on NK
cells (30).
MOLECULES INVOLVED IN PLATELET–TUMOR INTERACTION
Tumor cell interaction with platelets, leukocytes, and endothe-
lium is mediated mainly by integrins and their ligands and by
the binding of P-selectin with selectin ligands expressed on tumor
cells.
INTEGRINS
Integrins are transmembrane glycoproteins composed of an α and
a β subunits forming a non-covalent heterodimer that promote
cell–cell and cell–extracellular matrix adhesion, and modulates
multiple cellular processes such as cell migration, proliferation,
and survival. Integrins become activated through a process involv-
ing an “inside-out” signal from other receptors that results in a
change in the integrin structure from a low affinity conformation
to a high affinity form that enables ligand binding (31).
During the hematogenous phase of metastasis, binding of sol-
uble platelet agonists to their receptors elicit various signaling
transduction events that ultimately induce inside-out signaling
processes that culminate in activation of the ligand-binding func-
tion of integrin αIIbβ3 (GPIIb/IIIa) and granule secretion (10).
The homotypic interaction between platelets occurs via cross-
linking of integrins, primarily αIIbβ3, by adhesive ligands that
serve as bridging proteins present in plasma or released from acti-
vated platelets, including fibrinogen, fibronectin, von Willebrand
factor (vWF), and other ligands containing the arginine–glycine–
aspartate (RGD) integrin-binding domain (32). Ligand binding
to integrin αIIbβ3 then mediates platelet aggregation and triggers
“outside-in” signaling that amplifies platelet response, resulting
in the stabilization of platelet adhesion and aggregation, and clot
retraction.
Platelet–tumor cell aggregates result from cross-linking of
platelet integrins, primarily αIIbβ3, with integrins expressed on
tumor cells, such as αvβ3, by the above mentioned adhesive lig-
ands (33). The relevance of αIIbβ3 and αvβ3 interaction in tumor
metastasis has been demonstrated in in vivo models, which showed
a decrease of pulmonary metastasis following inhibition of αvβ3
with a specific monoclonal antibody,an effect that was significantly
reduced after platelet depletion (34).αIIbβ3 andαvβ3 integrins also
support the arrest of tumor cells to the endothelium of metasta-
tic sites. Other integrins such as α5β1 and α3β1 as well as the
adhesive ligands vitronectin and laminin have been implicated in
platelet–tumor interaction, tumor adhesion, and metastasis (35)
(Figure 1).
SELECTINS
Selectins are cell-surface adhesion molecules with a carbohydrate-
binding domain that bind with low affinity to sialylated and fuco-
sylated glycan structures present on selectin ligands and induce
integrin activation. Several studies have shown that selectins may
transduce outside-in signals upon interaction with their ligands
(36, 37). In cancer cell interactions, selectins expressed on platelets,
leukocytes, and endothelium bind to selectin ligands present on
tumor cells, leading to the formation of platelet–tumor-leukocyte
aggregates and tumor cell arrest in the microvasculature (38).
The selectin family consists of three molecules with selective
cell distribution. P-selectin is stored in the alpha and dense gran-
ules of platelets and in the Weibel–Palade bodies of endothelial
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FIGURE 1 | Molecules involved in platelet–tumor cell interaction.
Platelet–tumor cell aggregates are formed (1) by cross-linking of platelet
integrins, primarily αIIbβ3 integrins, with αvβ3 integrin expressed on tumor
cells through their ligands, which act as bringing molecules (Fg, FN, fibrin,
and vWF), (2) by interaction of platelet P-selectin with its selectin-ligands
expressed on tumor cells (PSGL-1, CD44, CD24). The ectopic expression of
megakaryocytic genes in various tumor cells leads to the expression of
functional αIIbβ3, and therefore, the heterotypic interaction between platelets
and tumor cells may take place through cross-linking of this integrin. Other
integrins has also been suggested to participate in platelet–tumor
aggregates formation. FN, fibronectin; Fg, fibrinogen; vWF, von Willebrand
factor; VN, vitronectin.
cells and translocated to surface upon cellular activation by ago-
nists. P-selectin binds to a variety of human cancer cells, such
as colon, lung, and breast cancer, as well as melanoma and neu-
roblastoma (39). Platelets from P-selectin-deficient mice exhibit
a reduced interaction with tumor cells, resulting in a marked
decrease of metastasis and reflecting the importance of this protein
in tumor progression (40, 41). L-selectin, a molecule constitutively
expressed on the majority of leukocytes, enables leukocyte hom-
ing to lymphoid organs and extravasation into inflamed tissues.
This molecule facilitates tumor metastasis and acts synergistically
with P-selectin (42). Although E-selectin, expressed on endothe-
lial cells, has not been implicated in platelet–tumor interaction,
it participates in the homing of metastatic cancer cells to distant
organs (43).
SELECTIN LIGANDS
The tetrasaccharide sialyl-Lewisx (sLex) and its isomer sialyl-
Lewisa (sLea) recognized by selectins are located in terminal chains
of glycolipids and N-/O-glycoproteins displayed on selectin lig-
ands. High cell-surface expression of sLex and sLea or altered
glycosylation on tumor cells has been associated with tumor pro-
gression and metastasis (44). Selectin ligands are mainly sialylated,
fucosylated, sulfated glycans localized on tumor cell mucins, that
is, heavily glycosylated proteins with O-linked oligosaccharides.
Several mucin-like molecules with P-selectin ligand activity
have been identified. P-selectin glycoprotein ligand-1 (PSGL-1)
is a sialylated mucin-type disulfide-linked homodimer expressed
on most leukocytes, which presents a high-affinity binding to P-
selectin and is essential for the homing of leukocytes to tissue.
PSGL-1 has also been described as a P-selectin ligand on lung
cancer and myeloma cells, and an E-selectin ligand on prostate
tumor cells (45–47). CD24 modified by sLex serves as the major
P-selectin-reactive ligand on the surface of breast cancer cells and
its enhanced expression is related to cancer progression and poor
prognosis (48, 49). CD44 variant isoforms (CD44v) act as E-/L-/P-
selectin ligands on colon cancer cells and as E-selectin ligand on
breast cancer cells (50, 51). Podocalyxin-like protein 1 (PCLP1),
a cell-surface sialomucin expressed in a wide range of normal cell
as well as in various types of cancer, has been also associated with
metastasis (52).
PCLP1, A SELECTIN LIGAND INVOLVED IN PLATELET–TUMOR
INTERACTION
Podocalyxin-like protein 1 is a cell-surface glycoprotein that
belongs to the CD34 family of sialomucins (53). Initially iden-
tified on kidney podocytes, PCLP1 is widely expressed on vascular
endothelium, mesothelial cells, hematopoietic stem and progeni-
tor cells, a subset of neuronal cells, and platelets (54–58). PCLP1
is attached to the actin cytoskeleton through its association with
ezrin, a protein that regulates cell adhesion, motility, and survival
(59). In renal glomerular podocytes, PCLP1 functions as an anti-
adhesive molecule, which plays a vital role in maintaining opened
the filtration slits due to its highly negative charge, as evidenced
by the observation of severe renal malformation and anuria in
PCLP1-deficient mice (60). On the contrary, in high endothelial
venules, PCLP1 serves as a pro-adhesive molecule participating
in the tethering and rolling of lymphocytes via interaction with
L-selectin (53). During embryonic development, PCLP1 expres-
sion by mesothelial cells is required for the retraction of the gut
from the umbilical cord (60). In the hematopoietic system, PCLP1
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participates in cell migration to distant hematopoietic tissues (56).
PCLP1 is also involved in neuronal development and synapse
formation (61).
The overexpression of PCLP1 has been associated with a more
aggressive phenotype and poor prognosis in numerous types of
cancer, including breast, colorectal, prostate, bladder, ovarian can-
cer, renal carcinoma, and oral squamous cell carcinoma, which
suggests an important role of this protein in cancer progression
and metastasis, although the underlying mechanisms are poorly
understood (62–69). PCLP1 is also overexpressed in blasts of acute
leukemia, testicular tumor, hepatic carcinoma, astrocytic tumor,
and small cell lung carcinoma (70–74). PCLP1 increases in vitro
migration and invasion of tumor cells through its interaction
with ezrin in breast cancer cells (75) and promotes invadopo-
dia formation and metastasis by activating Rac1/Cdc42/cortactin
signaling cascade (76). Recently, it has been demonstrated that
PCLP1 expression in A549 human lung carcinoma cell line is
increased during TGF-β-induced epithelial–mesenchymal tran-
sition and regulates the molecular changes associated with this
process (77).
Although data support a correlation between PCLP1 expres-
sion and enhanced binding of metastatic tumor cells to selectins,
evidences showing a functional role of PCLP1 as a selectin-ligand
in cancer are limited. Recent reports show that PCLP1 expressed
on colon carcinoma or pancreatic cells display E- and L-, but not
P-, selectin-mediated adhesion under flow conditions (78, 79).
The first study was conducted by perfusing E- and P-selectin-
expressing Chinese Ovarian (CHO) cells and L-selectin-expressing
human peripheral blood lymphocytes over purified PCLP1 pro-
tein derived from colon carcinoma cells and by cell-free flow-based
adhesion assays using PCLP1-coated microspheres (78). Interest-
ingly, the results proved that carbohydrate determinants involved
in binding of PCLP1 expressed in colon carcinoma cells to L-
and E-selectins differ from that displayed by PCLP1 expressed
in high endothelial venules. The second report used PCLP1-
knockdown pancreatic cells perfused over immobilized E- and
L-selectin, demonstrating that PCLP1 is functionally relevant in
tumor cell-selectin interaction (79).
The role for PCLP1 in promoting cell–platelet interactions is
supported by a study performed in Tera-1 cell line, derived from
an embryonal carcinoma of the testis expressing high levels of
PCLP1, and in CHO cells ectopically expressing PCLP1 (80).
This report provided evidence that PCLP1 increases the adhe-
sion of cells to fibrinogen-immobilized platelets in a sialylation-
dependent manner, further enhanced by activation of platelets by
agonist. PCLP1-induced adhesion is partially inhibited by block-
ers of P-selectin and by an inhibitor of integrins αvβ3/αvβ5, and
almost totally restrained by RGD peptide, a potent inhibitor of
many integrin–ligand interactions, indicating the contribution of
these adhesion molecules to this process. Besides, PCLP1 colo-
calizes with P-selectin expressed on activated platelets at cell
contact sites. Another report demonstrated that PCLP1 increases
cell adherence to human vascular endothelial cells, an effect that
is amplified after stimulation of these cells with thrombin or
histamine (81). Furthermore, PCLP1 enhances cell adhesion to
immobilized fibronectin as well as cell spreading and migration.
PCLP1-mediated cell adhesion to fibronectin is also dependent on
the activity of integrins, as it is prevented by RGD peptides or by
inhibitors of αvβ3 integrin, whereas cell spreading is controlled by
α5β1 integrin.
Fibronectin, a protein that forms part of the extracellular
matrix, is also abundant in plasma and mediates platelet aggre-
gation by binding β3 integrins and tethering adjacent platelets
(82, 83). It has been reported that incorporation of plasma
fibronectin into fibrin clots enhances metastasis to the lungs
(84). Thus, the ability of PCLP1 to potentiate cell binding to
fibronectin through the activation of integrins could increase
the interaction of platelets with tumor cells, fibronectin act-
ing as a bridge molecule between αvβ3 or αvβ5 expressed on
tumor cells and αIIbβ3, αvβ3, and α5β1 integrins expressed on
platelets. Subsequently, the interaction between fibronectin and
integrins might trigger outside-in signals that would potentiate
the activation state of platelets, thereby stabilizing the aggregates.
Other adhesive molecules such as fibrinogen, vitronectin, fib-
rin, and vWF could also serve as bridge proteins in this process
(Figure 2).
Although the signaling triggered in platelet by the interac-
tion of P-selectin with PCLP1 has not been explored so far, it
is known that selectins may transduce outside-in signals delivered
by selectin ligands through their cytoplasmic tail (36). In that way,
binding of PSGL-1 to P-selectin expressed on platelets induces
calcium influx and a signaling cascade that triggers αIIbβ3 acti-
vation, microaggregates generation, and thrombus formation (85,
86). Platelet activation is followed by the phosphorylation of tyro-
sine, serine, threonine, and histidine residues on the cytoplasmic
tail of P-selectin (87–89). Similarly, the interaction of PCLP1 with
P-selectin might induce outside-in signals that could ultimately
lead to enhanced expression of adhesion molecules on platelets
that would reinforce platelet–tumor cell–leukocytes aggregates,
creating a positive feedback loop.
As mentioned previously, PCLP1 is also expressed on acti-
vated platelets. Mice overexpressing human PCLP1 on platelets
exhibit a phenotype characterized by decreased bleeding time
and enhanced platelet aggregation after agonist stimulation (90).
Inversely, the deletion of pclp1 gene in mouse platelets produce a
prolonged bleeding time, decreased platelet aggregation, decreased
in vivo thrombosis, and reduced adherence of platelets to fib-
rinogen under flow, all this pointing to a role of PCLP1 in the
control of hemostasis (91). Thereby, PCLP1 expressed on platelet
could strengthen the heterotypic conjugates formation during
hematogenous metastasis and promote their retention to the ves-
sel wall of target organs by enhancing cell adhesion to fibronectin
localized on subendothelial matrix, which is exposed following
endothelial cell retraction at metastatic sites.
Considering the aforementioned observations, we hypothesize
that PCLP1 could have a role in the escape of tumor cells from
the immune surveillance by inducing platelet–tumor interaction.
PCLP1 might participate in tumor cell evasion by fostering the
formation of a physical barrier to NK cell-mediated cytotoxicity
comprised of platelets and adhesive proteins through the mecha-
nisms described above. Moreover, PCLP1 contribution to platelet–
tumor interaction with vascular endothelial cells may result in a
decreased permanence of hetero-aggregates in the bloodstream,
thereby diminishing their exposure to NK cells.
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FIGURE 2 | Role of PCLP1 in platelet–tumor cell interaction. The ability
of PCLP1 to potentiate cell binding to fibronectin through the activation of
integrins could increase the interaction of platelets with tumor cells.
Fibronectin would act as a bridge molecule between αvβ3 or αvβ5 expressed
on tumor cells and αIIbβ3, αvβ3, and α5β1 integrins expressed on platelets.
This interaction might trigger outside-in signals that would potentiate the
activation state of platelets, eventually leading to the stabilization of the
hetero-aggregates. Moreover, PCLP1 binding to P-selectin could also result
in the generation of intracellular signaling that would reinforce the
hetero-aggregates.
FUTURE PERSPECTIVES
The evidence provided by the literature suggests that an anti-
PCLP1 antibody aimed at disrupting platelet–tumor aggregation
could be useful as a therapeutic drug for the treatment of PCLP1-
expressing cancers. As PCLP1 expression has also been reported
in normal tissues, including neuron, podocytes, and hematopoi-
etic stem cells, antibodies that display cross-reactivity with normal
cells may not be appropriate as therapeutic agents. Given that
selectin-binding determinants exhibited on PCLP1 expressed in
tumor cells are different from those described in normal cells
(78), an antibody recognizing specific glycan epitopes displayed
on tumor cells might avoid undesirable side effects. In addition
to antibodies, alternative antagonists may be used such as pep-
tides that block PCLP1–selectin interaction, specific aptamers,
which are oligonucleotides displaying high affinity and specificity
for target molecules, and glycomimetic compounds, synthetic
oligosaccharide analogs that mimic native carbohydrates.
A systematic study of PCLP1 contribution to the interaction
of platelet with different tumor types has not been addressed to
date. The functional properties of PCLP1 as an adhesive protein
that promotes platelet–tumor aggregates presented herein may
encourage researchers to reveal yet hidden aspects of this molecule.
ACKNOWLEDGMENTS
This work was supported by EITB Maratoia-BIOEF (Basque Foun-
dation for Health Innovation and Research) (BIO11/CM/007).
REFERENCES
1. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis.
Nat Rev Cancer (2011) 11(2):123–34. doi:10.1038/nrc3004
2. Varki A. Trousseau’s syndrome: multiple definitions and multiple mechanisms.
Blood (2007) 110(6):1723–9. doi:10.1182/blood-2006-10-053736
3. Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interaction in
solid tumors. Int J Cancer (2012) 130(12):2747–60. doi:10.1002/ijc.27441
4. Gil-Bernabe AM, Lucotti S, Muschel RJ. Coagulation and metastasis: what
does the experimental literature tell us? Br J Haematol (2013) 162(4):433–41.
doi:10.1111/bjh.12381
5. Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelet-cancer interactions.
Semin Thromb Hemost (2014) 40(3):296–305. doi:10.1055/s-0034-1370767
6. Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins,
and the inhibitory potential of heparins. Int J Cell Biol (2012) 2012:676731.
doi:10.1155/2012/676731
7. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat
Med (2006) 12(8):895–904. doi:10.1038/nm1469
8. Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooper-
ative host-tumor cell interactions during hematogenous dissemination. Cancer
Discov (2012) 2(12):1091–9. doi:10.1158/2159-8290.CD-12-0329
9. Boukerche H, Berthier-Vergnes O, Penin F, Tabone E, Lizard G, Bailly M, et al.
Human melanoma cell lines differ in their capacity to release ADP and aggregate
platelets. Br J Haematol (1994) 87(4):763–72. doi:10.1111/j.1365-2141.1994.
tb06736.x
10. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J
Thromb Haemost (2011) 9(2):237–49. doi:10.1111/j.1538-7836.2010.04131.x
11. Milsom C, Rak J. Tissue factor and cancer. Pathophysiol Haemost Thromb (2008)
36(3–4):160–76. doi:10.1159/000175154
12. Falanga A, Russo L, Milesi V. The coagulopathy of cancer. Curr Opin Hematol
(2014) 21(5):423–9. doi:10.1097/MOH.0000000000000072
13. Italiano JE Jr., Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S,
et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic
proteins are organized into separate platelet alpha granules and differentially
released. Blood (2008) 111(3):1227–33. doi:10.1182/blood-2007-09-113837
14. Peterson JE, Zurakowski D, Italiano JE Jr., Michel LV, Fox L, Klement GL, et al.
Normal ranges of angiogenesis regulatory proteins in human platelets. Am J
Hematol (2010) 85(7):487–93. doi:10.1002/ajh.21732
15. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells
by natural killer cells in mice is impeded by platelets. Cancer Res (1999)
59(6):1295–300.
16. Gorelik E, Wiltrout RH, Okumura K, Habu S, Herberman RB. Role of NK cells
in the control of metastatic spread and growth of tumor cells in mice. Int J
Cancer (1982) 30(1):107–12. doi:10.1002/ijc.2910300118
17. Hanna N. The role of natural killer cells in the control of tumor growth and
metastasis. Biochim Biophys Acta (1985) 780(3):213–26.
18. Lanier LL. NK cell recognition. Annu Rev Immunol (2005) 23:225–74. doi:10.
1146/annurev.immunol.23.021704.115526
19. Della Chiesa M, Carlomagno S, Frumento G, Balsamo M, Cantoni C, Conte R,
et al. The tryptophan catabolite l-kynurenine inhibits the surface expression of
NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood
(2006) 108(13):4118–25. doi:10.1182/blood-2006-03-006700
20. Yakar I, Melamed R, Shakhar G, Shakhar K, Rosenne E, Abudarham N,
et al. Prostaglandin e(2) suppresses NK activity in vivo and promotes post-
operative tumor metastasis in rats. Ann Surg Oncol (2003) 10(4):469–79.
doi:10.1245/ASO.2003.08.017
www.frontiersin.org September 2014 | Volume 4 | Article 245 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amo et al. PCLP1 in platelet–tumor interaction
21. Sabry M, Lowdell MW. Tumor-primed NK cells: waiting for the green light.
Front Immunol (2013) 4:408. doi:10.3389/fimmu.2013.00408
22. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, et al.
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D
receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl
Acad Sci U S A (2003) 100(7):4120–5. doi:10.1073/pnas.0730640100
23. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW,
et al. Platelets and fibrin(ogen) increase metastatic potential by impeding nat-
ural killer cell-mediated elimination of tumor cells.Blood (2005) 105(1):178–85.
doi:10.1182/blood-2004-06-2272
24. Zheng S, Shen J, Jiao Y, Liu Y, Zhang C, Wei M, et al. Platelets and fibrinogen
facilitate each other in protecting tumor cells from natural killer cytotoxicity.
Cancer Sci (2009) 100(5):859–65. doi:10.1111/j.1349-7006.2009.01115.x
25. Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta
down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactiv-
ity. Cancer Res (2009) 69(19):7775–83. doi:10.1158/0008-5472.CAN-09-2123
26. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal
transition. Cell Res (2009) 19(2):156–72. doi:10.1038/cr.2009.5
27. Gersuk GM, Westermark B, Mohabeer AJ, Challita PM, Pattamakom S, Pat-
tengale PK. Inhibition of human natural killer cell activity by platelet-derived
growth factor (PDGF). III. Membrane binding studies and differential biological
effect of recombinant PDGF isoforms. Scand J Immunol (1991) 33(5):521–32.
doi:10.1111/j.1365-3083.1991.tb02522.x
28. Gersuk GM, Chang WC, Pattengale PK. Inhibition of human natural killer cell
activity by platelet-derived growth factor. II. Membrane binding studies, effects
of recombinant IFN-alpha and IL-2, and lack of effect on T cell and antibody-
dependent cellular cytotoxicity. J Immunol (1988) 141(11):4031–8.
29. Cao Y. Multifarious functions of PDGFs and PDGFRs in tumor growth and
metastasis. Trends Mol Med (2013) 19(8):460–73. doi:10.1016/j.molmed.2013.
05.002
30. Placke T, Salih HR, Kopp HG. GITR ligand provided by thrombopoietic
cells inhibits NK cell antitumor activity. J Immunol (2012) 189(1):154–60.
doi:10.4049/jimmunol.1103194
31. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell (2002)
110(6):673–87. doi:10.1016/S0092-8674(02)00971-6
32. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ
Res (2007) 100(12):1673–85. doi:10.1161/01.RES.0000267878.97021.ab
33. Felding-Habermann B, Habermann R, Saldivar E, Ruggeri ZM. Role of beta3
integrins in melanoma cell adhesion to activated platelets under flow. J Biol
Chem (1996) 271(10):5892–900. doi:10.1074/jbc.271.10.5892
34. Lonsdorf AS, Kramer BF, Fahrleitner M, Schonberger T, Gnerlich S, Ring S, et al.
Engagement of alphaIIbbeta3 (GPIIb/IIIa) with alphanubeta3 integrin medi-
ates interaction of melanoma cells with platelets: a connection to hematogenous
metastasis. J Biol Chem (2012) 287(3):2168–78. doi:10.1074/jbc.M111.269811
35. McNicol A, Israels SJ. Beyond hemostasis: the role of platelets in inflamma-
tion, malignancy and infection. Cardiovasc Hematol Disord Drug Targets (2008)
8(2):99–117. doi:10.2174/187152908784533739
36. Lorenzon P,Vecile E, Nardon E, Ferrero E, Harlan JM, Tedesco F, et al. Endothelial
cell E- and P-selectin and vascular cell adhesion molecule-1 function as signaling
receptors. J Cell Biol (1998) 142(5):1381–91. doi:10.1083/jcb.142.5.1381
37. Simon SI, Cherapanov V, Nadra I, Waddell TK, Seo SM, Wang Q, et al. Signal-
ing functions of L-selectin in neutrophils: alterations in the cytoskeleton and
colocalization with CD18. J Immunol (1999) 163(5):2891–901.
38. Laubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol
(2010) 20(3):169–77. doi:10.1016/j.semcancer.2010.04.005
39. Chen M, Geng JG. P-selectin mediates adhesion of leukocytes, platelets, and
cancer cells in inflammation, thrombosis, and cancer growth and metastasis.
Arch Immunol Ther Exp (Warsz) (2006) 54(2):75–84. doi:10.1007/s00005-006-
0010-6
40. Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor
growth and metastasis. Proc Natl Acad Sci U S A (1998) 95(16):9325–30.
doi:10.1073/pnas.95.16.9325
41. Qi CL, Wei B, Ye J, Yang Y, Li B, Zhang QQ, et al. P-selectin-mediated platelet
adhesion promotes the metastasis of murine melanoma cells. PLoS One (2014)
9(3):e91320. doi:10.1371/journal.pone.0091320
42. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and
P-selectin in facilitating tumor metastasis can involve non-mucin ligands and
implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A (2002)
99(4):2193–8. doi:10.1073/pnas.261704098
43. Brodt P, Fallavollita L, Bresalier RS, Meterissian S, Norton CR, Wolitzky BA.
Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes
liver metastasis. Int J Cancer (1997) 71(4):612–9. doi:10.1002/(SICI)1097-
0215(19970516)71:4<612::AID-IJC17>3.3.CO;2-1
44. Hauselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis.
Front Oncol (2014) 4:28. doi:10.3389/fonc.2014.00028
45. Gong L, Cai Y, Zhou X, Yang H. Activated platelets interact with lung cancer cells
through P-selectin glycoprotein ligand-1. Pathol Oncol Res (2012) 18(4):989–96.
doi:10.1007/s12253-012-9531-y
46. Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, et al.
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma
cells with the bone marrow microenvironment. Blood (2012) 119(6):1468–78.
doi:10.1182/blood-2011-07-368050
47. Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, et al. Iden-
tification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and
E-selectin ligand-1, on human metastatic prostate tumor cells.Cancer Res (2005)
65(13):5750–60. doi:10.1158/0008-5472.CAN-04-4653
48. Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt
P, et al. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J
(1998) 12(12):1241–51.
49. Fang X, Zheng P, Tang J, Liu Y. CD24: from A to Z. Cell Mol Immunol (2010)
7(2):100–3. doi:10.1038/cmi.2009.119
50. Alves CS, Burdick MM, Thomas SN, Pawar P, Konstantopoulos K. The dual
role of CD44 as a functional P-selectin ligand and fibrin receptor in colon
carcinoma cell adhesion. Am J Physiol Cell Physiol (2008) 294(4):C907–16.
doi:10.1152/ajpcell.00463.2007
51. Burdick MM, Chu JT, Godar S, Sackstein R. HCELL is the major E- and L-
selectin ligand expressed on LS174T colon carcinoma cells. J Biol Chem (2006)
281(20):13899–905. doi:10.1074/jbc.M513617200
52. Nielsen JS, McNagny KM. The role of podocalyxin in health and disease. J Am
Soc Nephrol (2009) 20(8):1669–76. doi:10.1681/ASN.2008070782
53. Sassetti C, Tangemann K, Singer MS, Kershaw DB, Rosen SD. Identification
of podocalyxin-like protein as a high endothelial venule ligand for L-selectin:
parallels to CD34. J Exp Med (1998) 187(12):1965–75. doi:10.1084/jem.187.12.
1965
54. Kerjaschki D, Sharkey DJ, Farquhar MG. Identification and characterization of
podocalyxin – the major sialoprotein of the renal glomerular epithelial cell. J
Cell Biol (1984) 98(4):1591–6. doi:10.1083/jcb.98.4.1591
55. Horvat R, Hovorka A, Dekan G, Poczewski H, Kerjaschki D. Endothelial cell
membranes contain podocalyxin – the major sialoprotein of visceral glomerular
epithelial cells. J Cell Biol (1986) 102(2):484–91. doi:10.1083/jcb.102.2.484
56. Doyonnas R, Nielsen JS, Chelliah S, Drew E, Hara T, Miyajima A, et al. Podoca-
lyxin is a CD34-related marker of murine hematopoietic stem cells and embry-
onic erythroid cells.Blood (2005) 105(11):4170–8. doi:10.1182/blood-2004-10-
4077
57. Vitureira N, McNagny K, Soriano E, Burgaya F. Pattern of expression of the
podocalyxin gene in the mouse brain during development. Gene Expr Patterns
(2005) 5(3):349–54. doi:10.1016/j.modgep.2004.10.002
58. Miettinen A, Solin ML, Reivinen J, Juvonen E, Vaisanen R, Holthofer H. Podoca-
lyxin in rat platelets and megakaryocytes. Am J Pathol (1999) 154(3):813–22.
doi:10.1016/S0002-9440(10)65328-X
59. Orlando RA, Takeda T, Zak B, Schmieder S, Benoit VM, McQuistan T, et al.
The glomerular epithelial cell anti-adhesin podocalyxin associates with the
actin cytoskeleton through interactions with ezrin. J Am Soc Nephrol (2001)
12(8):1589–98.
60. Doyonnas R,Kershaw DB,Duhme C,Merkens H,Chelliah S,Graf T,et al. Anuria,
omphalocele, and perinatal lethality in mice lacking the CD34-related protein
podocalyxin. J Exp Med (2001) 194(1):13–27. doi:10.1084/jem.194.1.13
61. Vitureira N, Andres R, Perez-Martinez E, Martinez A, Bribian A, Blasi J, et al.
Podocalyxin is a novel polysialylated neural adhesion protein with multiple roles
in neural development and synapse formation. PLoS One (2010) 5(8):e12003.
doi:10.1371/journal.pone.0012003
62. Somasiri A, Nielsen JS, Makretsov N, McCoy ML, Prentice L, Gilks CB, et al.
Overexpression of the anti-adhesin podocalyxin is an independent predictor
of breast cancer progression. Cancer Res (2004) 64(15):5068–73. doi:10.1158/
0008-5472.CAN-04-0240
63. Forse CL, Yilmaz YE, Pinnaduwage D, O’Malley FP, Mulligan AM, Bull SB,
et al. Elevated expression of podocalyxin is associated with lymphatic invasion,
basal-like phenotype, and clinical outcome in axillary lymph node-negative
Frontiers in Oncology | Tumor Immunity September 2014 | Volume 4 | Article 245 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amo et al. PCLP1 in platelet–tumor interaction
breast cancer. Breast Cancer Res Treat (2013) 137(3):709–19. doi:10.1007/
s10549-012-2392-y
64. Larsson A, Johansson ME, Wangefjord S, Gaber A, Nodin B, Kucharzewska
P, et al. Overexpression of podocalyxin-like protein is an independent factor
of poor prognosis in colorectal cancer. Br J Cancer (2011) 105(5):666–72.
doi:10.1038/bjc.2011.295
65. Casey G, Neville PJ, Liu X, Plummer SJ, Cicek MS, Krumroy LM, et al. Podoca-
lyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol
Genet (2006) 15(5):735–41. doi:10.1093/hmg/ddi487
66. Boman K, Larsson AH, Segersten U, Kuteeva E, Johannesson H, Nodin B, et al.
Membranous expression of podocalyxin-like protein is an independent factor of
poor prognosis in urothelial bladder cancer. Br J Cancer (2013) 108(11):2321–8.
doi:10.1038/bjc.2013.215
67. Cipollone JA, Graves ML, Kobel M, Kalloger SE, Poon T, Gilks CB, et al. The anti-
adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of
high grade serous ovarian carcinoma. Clin Exp Metastasis (2012) 29(3):239–52.
doi:10.1007/s10585-011-9446-0
68. Hsu YH, Lin WL, Hou YT, Pu YS, Shun CT, Chen CL, et al. Podocalyxin
EBP50 ezrin molecular complex enhances the metastatic potential of renal
cell carcinoma through recruiting Rac1 guanine nucleotide exchange fac-
tor ARHGEF7. Am J Pathol (2010) 176(6):3050–61. doi:10.2353/ajpath.2010.
090539
69. Lin CW, Sun MS, Wu HC. Podocalyxin-like 1 is associated with tumor aggres-
siveness and metastatic gene expression in human oral squamous cell carcinoma.
Int J Oncol (2014) 45(2):710–8. doi:10.3892/ijo.2014.2427
70. Kelley TW, Huntsman D, McNagny KM, Roskelley CD, Hsi ED. Podocalyxin:
a marker of blasts in acute leukemia. Am J Clin Pathol (2005) 124(1):134–42.
doi:10.1309/7BHLAHHU0N4MHT7Q
71. Schopperle WM, Kershaw DB, DeWolf WC. Human embryonal carcinoma
tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem Biophys Res Commun
(2003) 300(2):285–90. doi:10.1016/S0006-291X(02)02844-9
72. Chen X, Higgins J, Cheung ST, Li R, Mason V, Montgomery K, et al. Novel
endothelial cell markers in hepatocellular carcinoma. Mod Pathol (2004)
17(10):1198–210. doi:10.1038/modpathol.3800167
73. Hayatsu N, Kaneko MK, Mishima K, Nishikawa R, Matsutani M, Price JE, et al.
Podocalyxin expression in malignant astrocytic tumors. Biochem Biophys Res
Commun (2008) 374(2):394–8. doi:10.1016/j.bbrc.2008.07.049
74. Koch LK, Zhou H, Ellinger J, Biermann K, Holler T, von Rucker A, et al. Stem
cell marker expression in small cell lung carcinoma and developing lung tissue.
Hum Pathol (2008) 39(11):1597–605. doi:10.1016/j.humpath.2008.03.008
75. Sizemore S, Cicek M, Sizemore N, Ng KP, Casey G. Podocalyxin increases the
aggressive phenotype of breast and prostate cancer cells in vitro through its
interaction with ezrin. Cancer Res (2007) 67(13):6183–91. doi:10.1158/0008-
5472.CAN-06-3575
76. Lin CW, Sun MS, Liao MY, Chung CH, Chi YH, Chiou LT, et al. Podocalyxin-
like 1 promotes invadopodia formation and metastasis through activation of
Rac1/Cdc42/cortactin signaling in breast cancer cells. Carcinogenesis (2014).
doi:10.1093/carcin/bgu139
77. Meng X, Ezzati P, Wilkins JA. Requirement of podocalyxin in TGF-beta
induced epithelial mesenchymal transition. PLoS One (2011) 6(4):e18715.
doi:10.1371/journal.pone.0018715
78. Thomas SN, Schnaar RL, Konstantopoulos K. Podocalyxin-like protein is an
E-/L-selectin ligand on colon carcinoma cells: comparative biochemical proper-
ties of selectin ligands in host and tumor cells. Am J Physiol Cell Physiol (2009)
296(3):C505–13. doi:10.1152/ajpcell.00472.2008
79. Dallas MR, Chen SH, Streppel MM, Sharma S, Maitra A, Konstantopou-
los K. Sialofucosylated podocalyxin is a functional E- and L-selectin ligand
expressed by metastatic pancreatic cancer cells. Am J Physiol Cell Physiol (2012)
303(6):C616–24. doi:10.1152/ajpcell.00149.2012
80. Larrucea S, Butta N, Rodriguez RB, Alonso-Martin S, Arias-Salgado EG, Ayuso
MS, et al. Podocalyxin enhances the adherence of cells to platelets. Cell Mol Life
Sci (2007) 64(22):2965–74. doi:10.1007/s00018-007-7374-6
81. Larrucea S, Butta N, Arias-Salgado EG, Alonso-Martin S, Ayuso MS, Par-
rilla R. Expression of podocalyxin enhances the adherence, migration, and
intercellular communication of cells. Exp Cell Res (2008) 314(10):2004–15.
doi:10.1016/j.yexcr.2008.03.009
82. Cho J, Degen JL, Coller BS, Mosher DF. Fibrin but not adsorbed fibrinogen
supports fibronectin assembly by spread platelets. Effects of the interaction of
alphaIIb beta3 with the C terminus of the fibrinogen gamma-chain. J Biol Chem
(2005) 280(42):35490–8. doi:10.1074/jbc.M506289200
83. Cho J, Mosher DF. Role of fibronectin assembly in platelet thrombus formation.
J Thromb Haemost (2006) 4(7):1461–9. doi:10.1111/j.1538-7836.2006.01943.x
84. Malik G, Knowles LM, Dhir R, Xu S,Yang S, Ruoslahti E, et al. Plasma fibronectin
promotes lung metastasis by contributions to fibrin clots and tumor cell inva-
sion. Cancer Res (2010) 70(11):4327–34. doi:10.1158/0008-5472.CAN-09-3312
85. Theoret JF, Yacoub D, Hachem A, Gillis MA, Merhi Y. P-selectin ligation induces
platelet activation and enhances microaggregate and thrombus formation.
Thromb Res (2011) 128(3):243–50. doi:10.1016/j.thromres.2011.04.018
86. Sathish JG, Falati S, Croce K, Crump C, Furie BC, Furie B, et al. Anti-
body cross-linking of human platelet P-selectin induces calcium entry by a
mechanism dependent upon Fcgamma receptor IIA. Thromb Haemost (2004)
92(3):598–605. doi:10.1160/TH03-11-0689
87. Modderman PW, von dem Borne AE, Sonnenberg A. Tyrosine phosphoryla-
tion of P-selectin in intact platelets and in a disulphide-linked complex with
immunoprecipitated pp60c-src. Biochem J (1994) 299(Pt 3):613–21.
88. Fujimoto T, McEver RP. The cytoplasmic domain of P-selectin is phosphorylated
on serine and threonine residues. Blood (1993) 82(6):1758–66.
89. Crovello CS, Furie BC, Furie B. Histidine phosphorylation of P-selectin upon
stimulation of human platelets: a novel pathway for activation-dependent signal
transduction. Cell (1995) 82(2):279–86. doi:10.1016/0092-8674(95)90315-1
90. Alonso-Martin S, Nowakowski A, Larrucea S, Fernandez D, Vilar-Egea M,
Ayuso MS, et al. Overexpression of podocalyxin in megakaryocytes and platelets
decreases the bleeding time and enhances the agonist-induced aggregation of
platelets. Thromb Res (2010) 125(6):e300–5. doi:10.1016/j.thromres.2010.02.
008
91. Pericacho M, Alonso-Martin S, Larrucea S, Gonzalez-Manchon C, Fernandez
D, Sanchez I, et al. Diminished thrombogenic responses by deletion of the
podocalyxin gene in mouse megakaryocytes. PLoS One (2011) 6(10):e26025.
doi:10.1371/journal.pone.0026025
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 15 July 2014; accepted: 26 August 2014; published online: 11 September 2014.
Citation: Amo L, Tamayo-Orbegozo E, Maruri N, Eguizabal C, Zenarruzabeitia O,
Riñón M, Arrieta A, Santos S, Monge J, Vesga MA, Borrego F and Larrucea S (2014)
Involvement of platelet–tumor cell interaction in immune evasion. Potential role of
podocalyxin-like protein 1. Front. Oncol. 4:245. doi: 10.3389/fonc.2014.00245
This article was submitted to Tumor Immunity, a section of the journal Frontiers in
Oncology.
Copyright © 2014 Amo, Tamayo-Orbegozo, Maruri, Eguizabal, Zenarruzabeitia,
Riñón, Arrieta, Santos, Monge, Vesga, Borrego and Larrucea. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
www.frontiersin.org September 2014 | Volume 4 | Article 245 | 7
